Latest revenue
$432.0K
as of 2026-03-31
Latest net income
$-1.7M
as of 2026-03-31
Net margin
-389.1%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.3M
- Enterprise value
- $2.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $4.31
- 52-wk low
- $0.15
- Beta
- —
- Shares out
- 2.7M
5-year trend
What this company does
ITEM 1. BUSINESS Overview The registrant (together with our consolidated operating subsidiary, the “Company” or “Catheter”) was incorporated under the name “Ra Medical Systems, Inc.” as a Delaware corporation in July 2018. A predecessor had been incorporated in California in September of 2002, but was reincorporated in 2018 in connection with our initial public offering. The Company was initially formed to develop, commercialize and market an excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, including the DABRA product line. On January 9, 2023, the Company merged with Catheter Precision, Inc., or “Old Catheter”, a…
AI summary unavailable — showing raw filing excerpt
Generated from VTAK's filing dated 2026-03-31
Key risks
ITEM 1A. RISK FACTORS Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, before making an investment decision. The risks and uncertainties described below may not be the only ones we face. If any of the risks actually occur, our business, financial condition, operating results, cash flow and prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you could lose part or all of your investment. Risks Related to Our Financial Position and Need for Additional…
AI summary unavailable — showing raw filing excerpt
Generated from VTAK's filing dated 2026-03-31
Profitability
Gross margin
92.3%
2.6%Operating margin
-2581.6%
3.6%Net margin
-2098.0%
47.1%Return on equity
-243.6%
72.1%Return on assets
-108.3%
80.8%Leverage
Debt / equity
1.25×
8.3%Long-term debt / equity
0.44×
228.6%Debt / assets
55.5%
3.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $432.0K | +202.1% | $-1.7M | +58.4% | -389.1% |
Q4 2025 2025-12-31 | $238.0K | +59.7% | $-5.8M | -2.7% | -2427.7% |
Q3 2025 2025-09-30 | $226.0K | +135.4% | $-2.3M | +45.4% | -996.0% |
Q2 2025 2025-06-30 | $212.0K | +128.0% | $-5.1M | -21.1% | -2409.9% |
Q1 2025 2025-03-31 | $143.0K | +74.4% | $-4.0M | -51.2% | -2828.7% |
Q4 2024 2024-12-31 | $149.0K | — | $-5.6M | — | -3777.2% |
Q3 2024 2024-09-30 | $96.0K | -27.8% | $-4.1M | -113.8% | -4291.7% |
Q2 2024 2024-06-30 | $93.0K | -3.1% | $-4.2M | -167.8% | -4537.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on VTAK — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns VTAK
Institutional value
$12.3K
Total shares held
12.1K
Distinct holders
4
-5 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC | 11.4K | $11.5K | — | New |
| 2 | UBS Group AG | 759 | $767 | -779 (-50.7%) | Trimmed |
| 3 | SBI Securities Co., Ltd. | 5 | $5 | +0 (+0.0%) | No change |
| 4 | CITIGROUP INC | 1 | $1 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once VTAK's latest filing finishes processing.